Research programme: asthma therapeutics - BioLineRx

Drug Profile

Research programme: asthma therapeutics - BioLineRx

Alternative Names: EDP 26; EDP 28

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tel Aviv University
  • Developer BioLineRx; Tel Aviv University
  • Class Small molecules
  • Mechanism of Action Iron chelating agents; KCNQ potassium channel modulators; TRPV cation channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Asthma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in Asthma in Israel
  • 27 Sep 2013 Early research is ongoing in Israel
  • 24 Feb 2012 Early research in Asthma in Israel (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top